🔎 Trials Near Me

Home › Prostate Cancer › New York

Prostate Cancer clinical trials in New York

126 studies for Prostate Cancer are looking for participants at sites in New York.

Cities in New York

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • Columbia University Medical Center, New York
  • Memorial Sloan Kettering, New York
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

  • Roswell Park Cancer Institute, Buffalo
  • Memorial Sloan Kettering Commack, Commack
  • Guthrie Cortland Memorial Hospital, Cortland
  • and 5 more
RecruitingPhase 3
Ages 18 and older · Men · Updated Oct 2, 2026 · NCT06931340

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

  • Roswell Park Cancer Institute, Buffalo
  • Memorial Sloan Kettering Commack, Commack
  • Memorial Sloan Kettering Westchester, Harrison
  • and 4 more
RecruitingPhase 3
Ages 18 and older · Men · Updated Oct 2, 2026 · NCT07200830

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

  • NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
  • NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
  • Icahn School of Medicine at Mount Sinai, New York
  • and 2 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06465069

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Queens Hospital Center, Jamaica
  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
  • Stony Brook University Medical Center, Stony Brook
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Oct 2, 2026 · NCT05334069

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

  • Roswell Park Cancer Institute, Buffalo
  • Mount Sinai Hospital, New York
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06632977

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

  • Roswell Park Cancer Institute IDS, Buffalo
  • Memorial Sloan Kettering Hospital, New York
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06172478

Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients

  • Kings County Hopsital Center, Brooklyn
  • Queens Cancer Center of Queens Hospital, Jamaica
  • Memorial Sloan Kettering at Ralph Lauren Center (Limited Protocol Activities), New York
  • and 1 more
Recruiting
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT04751435

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  • Memorial Sloan Kettering Commack, Commack
  • Memorial Sloan Kettering Westchester, Harrison
  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
  • and 3 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT03866382

A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

  • Herbert Irving Comprehensive Cancer Center Columbia University Medical Center, New York
RecruitingPhase 1
Ages 18 and older · Men · Updated Sep 28, 2026 · NCT06095089

Precision-Based Genomics in Prostate Cancer

  • Memorial Sloan Kettering Cancer Center, New York
  • Mount Sinai Hospital, New York
  • Weill Cornell Medicine, New York
RecruitingObservational study
Ages 18 to 120 · Men · Updated Sep 28, 2026 · NCT04706663

Prostate Cancer Risk Identification in a Multi-Ethnic Cohort: a Prospective US-based Multi-center Validation Study of Proclarix

  • Crystal Run Healthcare, Middletown
RecruitingObservational study
Ages 40 to 75 · Men · Updated Sep 28, 2026 · NCT07543757

A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer

  • Associated Medical Professionals, Syracuse
RecruitingPhase 2
Ages 18 and older · Men · Updated Sep 25, 2026 · NCT07832292

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

  • Research Site, New York
RecruitingPhase 1/2
Ages 18 to 130 · Men · Updated Sep 25, 2026 · NCT07181161

Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer

  • Memorial Sloan Kettering Cancer Center, Long Island City
  • Associated Medical Professionals, Syracuse
RecruitingPhase 1/2
Ages 18 and older · Men · Updated Sep 25, 2026 · NCT06800313

A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer

  • Columbia University Medical Center, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07319871

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

  • Associated Medical Professionals - Urology ( Site 0081), Syracuse
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06136650

A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer

  • Columbia University Medical Center, New York
RecruitingPhase 1
Ages 18 and older · Men · Updated Sep 25, 2026 · NCT07082920

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

  • MSK Commack, Commack
  • MSKCC-Westchester (500 Westchester Ave.), Harrison
  • Integrated Medical Professionals, Lake Success
  • and 10 more
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 24, 2026 · NCT07028853

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

  • Mount Sinai Hosp Med School, New York
  • Associated Med Professionals of NY, Syracuse
  • Montefiore Medical Center, The Bronx
RecruitingPhase 2/3
Ages 18 to 100 · Men · Updated Sep 22, 2026 · NCT06780670

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

  • New York University (NYU) Langone Medical Center, New York
  • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07114601

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

  • Hematology Oncology Association of Central New York, East Syracuse
  • Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 22, 2026 · NCT07213674

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

  • Bassett Medical Center, Cooperstown
  • Weill Cornell Medicine NY-Presb, New York
  • University of Rochester Medical Ctr, Rochester
  • and 2 more
RecruitingPhase 3
Ages 18 to 100 · Men · Updated Sep 22, 2026 · NCT06855277

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

  • Research Site, New York
  • Research Site, Syracuse
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 18, 2026 · NCT06952803

Comparing Two Different Boost Approaches in Radiation Therapy for People With Prostate Cancer

  • Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities), Commack
  • Memorial Sloan Kettering at Westchester (Limited Protocol Activities), Harrison
  • Weill Cornell Medical Center (Data Collection Only), New York
  • and 2 more
RecruitingPhase 3
All ages · Men · Updated Sep 18, 2026 · NCT07548164

Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

  • Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY, New York
RecruitingPhase 2
Ages 18 and older · Men · Updated Sep 17, 2026 · NCT04038502

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

  • Icahn School of Medicine at Mount Sinai ( Site 0009), New York
  • Great Lakes Cancer Care ( Site 0047), Williamsville
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 17, 2026 · NCT06925737

A Study of Changes to Prostate Procedures

  • Memorial Sloan Kettering Suffolk-Commack (Consent only), Commack
  • Memorial Sloan Kettering Westchester (Consent Only), Harrison
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
  • and 1 more
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 15, 2026 · NCT06986083

PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness

  • Memorial Sloan Kettering Cancer Center, New York
RecruitingObservational study
Ages 18 and older · Men · Updated Sep 15, 2026 · NCT04995198

MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)

  • Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 2
Ages 18 and older · Men · Updated Sep 15, 2026 · NCT06150417

The SUGAR Study; SBRT and Relugolix) for Prostate Cancer

  • Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 2
Ages 18 and older · Men · Updated Sep 14, 2026 · NCT06111781

Sacral Neuromodulation for Male Overactive Bladder (MOAB)

  • Integrated Medical Professionals, New York
Recruiting
Ages 18 and older · Men · Updated Sep 14, 2026 · NCT06511141

Transperineal Micro-ultrasound for the Detection of Prostate Cancer During Biopsy

  • Roswell Park Cancer Institute, Buffalo
Recruiting
Ages 18 and older · Men · Updated Sep 11, 2026 · NCT07075705

[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate or Salivary Gland Cancer

  • Memorial Sloan Kettering Commack (Consent only), Commack
  • Memorial Sloan Kettering Westchester (Consent only), Harrison
  • Memorial Sloan Kettering Cancer Center, New York
  • and 1 more
Recruiting
All ages · Men · Updated Sep 11, 2026 · NCT00588185

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

  • Albany Medical College, Department of Urology, Albany
  • Mount Sinai Doctors Urology Faculty Practice, New York
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 11, 2026 · NCT06056830

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

  • Northwell Health Imbert Cancer Center, Bay Shore
  • New York-Presbyterian/Brooklyn Methodist Hospital, Brooklyn
  • Sands Cancer Center, Canandaigua
  • and 19 more
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 10, 2026 · NCT05946213

Short Course ADT for High Risk Low/Intermediate Risk ARTERA Prostate Cancer

  • NYU Langone Health, New York
RecruitingPhase 2
Ages 18 and older · Men · Updated Sep 3, 2026 · NCT07801664

A Study of Tarlatamab for People With Prostate Cancer

  • Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
  • and 1 more
RecruitingPhase 2
Ages 18 and older · Men · Updated Aug 31, 2026 · NCT07111507

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

  • New York Cancer & Blood Specialists, New York
  • University of Rochester - Wilmot Cancer Institute, Rochester
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 27, 2026 · NCT06582017

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.